MISSISSAUGA, ON, June 29 /CNW/ - YM BioSciences Inc. (NYSE Amex:  YMI,
TSX:YM, AIM:YMBA), a life sciences product development company that identifies
and advances a diverse portfolio of promising cancer-related products at
various stages of development, today reported that YM's subsidiary, CIMYM
BioSciences Inc. and Oncoscience AG have resolved the issues between the
companies in a cooperative effort. CIMYM BioSciences has formally notified
Oncoscience that it no longer intends to submit its application to the London
Court of International Arbitration for resolution of the matters previously in
    "We are pleased that CIMYM BioSciences and Oncoscience have resolved
their differences amicably at a minimal cost to either party and that each are
committed to cooperate fully in moving nimotuzumab forward clinically with all
due deliberate speed," said David Allan, Chairman and CEO of YM BioSciences.
"The late-stage European clinical program Oncoscience is undertaking
contributes significantly to the broad program being advanced by the network
of cooperative relationships dedicated to the development of this important
cancer drug globally."
    "Its unique safety profile and efficacy make nimotuzumab a very promising
and innovative treatment option with the potential to maintain a high quality
of life for patients suffering from a number of different cancer indications,"
added Ferdinand Bach, CEO of Oncoscience. "I am delighted that we may now
focus our combined resources exclusively on the contribution to the clinical
program being undertaken globally for this promising drug. Recruitment of our
Phase III trial in newly diagnosed pediatric pontine glioma has been concluded
and we anticipate that recruitment in our randomised Phase III trial in adult
glioblastoma grade IV will be completed in 2009. We are confident that data
from these trials, along with data that will come from our placebo controlled
randomised pancreatic cancer trial currently underway, in addition to data
from a well diversified clinical development program being advanced
internationally, will further strengthen and confirm the clinical value of

    About YM BioSciences

    YM BioSciences Inc. is a life sciences product development company that
identifies and advances a diverse portfolio of promising cancer-related
products at various stages of development. The Company is currently developing
two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized
Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of
free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical
trial expertise and a diversified business model designed to reduce risk while
advancing clinical products toward international approval, marketing and
    Nimotuzumab is a humanized monoclonal antibody in development worldwide,
targeting multiple tumor types primarily in combination with radiation and
chemoradiation. It is significantly differentiated from all other currently
marketed EGFR-targeting agents due to its remarkably benign side-effect
profile. Nimotuzumab's anti-tumor activity has led to its approval for
marketing in 18 countries. In more than 4000 patients reported as having been
treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation
dermatitis have been described, severe rash has not been observed and reports
of the other severe side-effects that are typical of EGFR-targeting molecules
have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary,
CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of
Molecular Immunology. YM is developing AeroLEF for the treatment of moderate
to severe acute pain. The product is differentiated from other approaches
using fentanyl because patients can individually control the analgesia
required for their differing intensities of pain. AeroLEF met all endpoints in
a randomized Phase II trial and is currently being prepared for late-stage
development internationally.

    About Oncoscience AG

    Oncoscience is a private company based in Wedel, Germany founded with the
goal developing treatments for rare diseases that are not being addressed by
major pharmaindustrial companies. Oncoscience's mission and therefore the
scientific benefit, lies in the research of rare diseases and the improvement
of therapeutic possibilities.
    Oncoscience's development program for cancer patients consist of its lead
drug candidate nimotuzumab and a fusion protein that is entering the clinic
this year to undergo Phase I trials. In the translational field, a first
patent was granted from the Australian government at the end of 2008.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(R) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or

For further information:

For further information: James Smith, the Equicom Group Inc., Tel. (416)
815-0700 x 229, Email: jsmith@equicomgroup.com; Thomas Fechtner, the Trout
Group LLC, Tel. (646) 378-2931, Email: tfechtner@troutgroup.com; Nominated
Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050 6500

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890